Atlas Trials

Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Clinical trial NCT07501169 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07501169
Sponsor
Sichuan University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Start date
2026-04-01
Primary completion
2027-08-31
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.